Clinical trials: Cognitive Control
Fall, Mild Cognitive Impairment (MCI)
Digital STEADI Efficacy
The aging of the U.S. population, combined with health care workforce shortages and insufficient access to effective fall prevention and exercise programs, has contributed to a high burden of fall-related injuries in older…
- Conditions
- Fall, Mild Cognitive Impairment (MCI), Aging
- Trial name
- NCT07852650
- Testing
- Digital STEADI-1, STEADI Standard of Care, Digital STEADI-2
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Friendi.fi Corporation
Neurogenic Detrusor Overactivity
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
The purpose of this study was to investigate a medicine for the treatment of symptoms and complications of neurogenic detrusor overactivity (NDO) in children and adolescents.
- Trial name
- NCT01565694
- Testing
- Solifenacin succinate
- Where
- 21 sites in United States, Belgium and 8 more
- Volunteers
- 76 people
- Sponsor
- Astellas Pharma Europe B.V.
Insomnia
Study of Efficacy of WELT-IP in Insomnia (WCTP-I-B-02)
The purpose of the study was to determine safety and efficacy of WELT-IP in adult insomnia patients. WELT-IP is a cognitive behavioral therapy for insomnia (CBT-I) based digital therapeutics.
- Trial name
- NCT05809544
- Testing
- WELT-IP
- Where
- South Korea
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- WELT corp
Cognitive Impairment
Ascending Dose Study of CT1812 in Healthy Volunteers
This is a double-blind, placebo controlled, ascending dose, multi-cohort trial. The study will be conducted in two phases: a single ascending dose (SAD) phase "Part A", followed by a multiple ascending dose (MAD) phase "Part B".
- Trial name
- NCT02570997
- Testing
- CT1812
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Cognition Therapeutics
Age-Related Cognitive Decline, Age-Related Memory Disorders
Memory Improvement With Docosahexaenoic Acid Study (MIDAS)
The purpose of this study is to investigate the effect of docosahexaenoic acid (DHA, 22:6n-3) in improving cognitive functions in subjects with age-related cognitive decline.
- Trial name
- MIDAS (NCT00278135)
- Where
- 14 sites in United States
- Volunteers
- 485 people
- Sponsor
- dsm-firmenich Switzerland AG
Cognitive Function
Nutrilite Memory Builder on the Improvement of Cognitive Function
Its a randomized controlled trial, to evaluate the effect of NUTRILITE Memory Builder on the improvement of cognitive function in middle-aged and elderly people.
- Trial name
- NCT05591885
- Testing
- Study product group (Nutrilite Memory Builder)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Amway (China) R&D Center
Cognitive Abilities
Enhancing Cognitive Abilities With Comprehensive Training
The purpose of this study is to measure the efficacy of an online cognitive training program against an active control condition in a large, randomized trial.
- Trial name
- NCT02367898
- Testing
- Lumosity Cognitive Training, Crossword Puzzles
- Where
- United States
- Volunteers
- 11,470 people, healthy volunteers welcome
- Sponsor
- Lumos Labs, Inc.
Schizophrenia
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
This is an efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.
- Trial name
- NCT01678755
- Testing
- ABT-126
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Cognition, Concentration
A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
This is a double-blind, randomized, 12-week parallel study that aims to determine the effects of a cognitive nutritional supplement for 12 weeks on cognition parameters specific to attention/focus related domains, compared to a…
- Conditions
- Cognition, Concentration, Attention, Focus
- Trial name
- NCT06837246
- Testing
- Cognitive Nutritional Supplement
- Where
- United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Pharmavite LLC
Cognitive Function
Radicle Clarity RPN: A Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes.
Radicle Clarity RPN: A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes.
- Trial name
- NCT07219641
- Testing
- Clarity Active Product 1, Clarity Active Product 2
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Radicle Science
Hyponatremia
Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients
Demonstrate an improvement in the composite scores of validated neurocognitive tests in elderly subjects with chronic sub-clinical (i.e., asymptomatic) hyponatremia.
- Trial name
- INSIGHT (NCT00550459)
- Testing
- Tolvaptan
- Where
- 12 sites in United States
- Volunteers
- 57 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with…
- Trial name
- CLIN-011 (NCT04739423)
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 41 people
- Sponsor
- CuraSen Therapeutics, Inc.
Healthy
Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults
This study is designed to look at the potential for an investigational drug (PF-04995274, under development by Pfizer, Inc. as a potential treatment for Alzheimer's disease) to reverse changes in memory and learning/problem…
- Trial name
- NCT01345864
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Pfizer
Mild Cognitive Impairment, Ischemic Stroke
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
The purpose of this study is: to evaluate efficacy of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke to evaluate safety of MMH-MAP in the treatment of mild…
- Trial name
- NCT03815292
- Testing
- MMH-MAP
- Where
- 28 sites in Russia
- Volunteers
- 276 people
- Sponsor
- Materia Medica Holding
Lennox-Gastaut Syndrome
Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs
This study was designed to evaluate the cognitive effect, safety, and pharmacokinetics (PK) of rufinamide on Lennox-Gastaut Syndrome (LGS) inadequately controlled in pediatric participants already taking other anti-epileptic…
- Trial name
- NCT01405053
- Testing
- Rufinamide, Any other approved Antiepileptic Drug
- Where
- 47 sites in United States, Canada and 5 more
- Volunteers
- 37 people
- Sponsor
- Eisai Inc.
Cognitive, Mood and Cognitive Performance
The Acute Effects of Onnit Alpha Brain on Cognition and Mood States
The purpose of this randomized, double-blind, placebo-controlled crossover study is to evaluate the efficacy of the acute effects of an investigational supplement (Alpha Brain or Alpha Brain 2.0) on improving cognitive…
- Conditions
- Cognitive, Mood and Cognitive Performance, Sleep Deprivation, Executive Function (Cognition)
- Trial name
- NCT07495592
- Testing
- Alpha Brain proprietary cognitive dietary supplement, Alpha Brain 2.0 proprietary cognitive dietary supplement
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Applied Science & Performance Institute
Depression in Remission
A Study of SDI-118 in Participants in Remission From Depression
This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on male and female study participants reporting…
- Trial name
- NCT05212116
- Testing
- SDI-118
- Where
- 3 sites in United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Syndesi Therapeutics
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Growth, Toddlers
Oral Nutritional Supplementation in Children With Growth Concerns
Multi-center, single-blinded, randomized, controlled study consisting of two arms, to investigate the impact of an oral nutritional supplement in combination with dietary counseling on growth in children with growth concerns as…
- Conditions
- Growth, Toddlers, Attention, Cognitive Function
- Trial name
- NCT07312201
- Testing
- Nutrient dense oral nutritional supplement
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Migraine Headache, Cognitive Impairment
Treximet in Acute Migraine Headache: Assessing Cognitive Function
Migraine headache occurs frequently in women more than men and is associated with symptoms not only of significant pain but also of symptoms typically including of photophobia, phonophobia, nausea and vomiting.
- Trial name
- NCT00837044
- Testing
- Treximet, Migraine rescue medication of choice
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Neurological Research Center